文献速递泌尿生殖MRUS

前列腺影像报告和数据系统第2版3类移行区病变男性的风险分层:活检总是必要的吗?

Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary?
PubMed 文献 · AJR Am J Roentgenol · 2017-08-31

研究纳入90例未行融合活检、共96个PI-RADSv2 3类移行区病变的男性,评估临床显著前列腺癌的预测因素。临床显著前列腺癌检出率为15%;联合PSAD≥0.15 ng/mL²与病灶ADC<1000 mm²/s的AUC为0.91,若仅以此标准活检可使60%检出临床显著前列腺癌,但8例(9%)假阴性。

要点

  • PI-RADSv2 3类移行区病变临床显著前列腺癌检出率仅15%。
  • PSAD≥0.15 ng/mL²且病灶ADC<1000 mm²/s联合标准AUC为0.91。
  • 按此标准限制活检仅10/90例需活检,但8例(9%)假阴性。

核心结论

  • PI-RADSv2 3类移行区病变男性融合活检临床显著前列腺癌检出率为15%,联合PSAD与ADC标准后可提升至60%(AUC>0.9),但存在9%假阴性。

研究设计与样本

  • 2014至2016年,865例男性接受前列腺MRI和MRI/US融合活检,其中90例未行融合活检的男性共96个PI-RADSv2 3类移行区病变纳入分析;3 T体线圈成像,由经验丰富的放射科医师分配PI-RADSv2类别;采用单变量和多变量分析寻找临床显著前列腺癌预测因素。

关键影像表现/征象

  • 96个PI-RADSv2 3类移行区病变中34个(35%)检出前列腺癌,其中14个(15%)为临床显著前列腺癌(Gleason评分≥3+4)。
  • 单变量分析中DWI评分、前列腺体积和PSAD是临床显著前列腺癌的显著预测因素(p<0.05),ADC和前列腺特异性抗原值提示有显著性(p<0.10)。
  • 多变量分析中PSAD和病灶ADC是最重要的协变量。

诊断标准与关键数值

  • PSAD≥0.15 ng/mL²且病灶ADC<1000 mm²/s联合预测临床显著前列腺癌的AUC为0.91(p<0.001)。
  • 若融合活检仅限上述标准,90例男性中仅10例接受活检,临床显著前列腺癌诊断率为60%,8例(9%)被误诊(假阴性)。

临床应用与阅片要点

  • 对于PI-RADSv2 3类移行区病变,可结合PSAD和病灶ADC进行风险分层以辅助活检决策。
  • 采用PSAD≥0.15 ng/mL²且ADC<1000 mm²/s标准限制活检时,需注意约9%的临床显著前列腺癌可能被漏诊。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The objective of our study was to determine the clinical and MRI characteristics of clinically significant prostate cancer (PCA) (Gleason score ≥ 3 + 4) in men with Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) category 3 transition zone (TZ) lesions.

MATERIALS AND METHODS: From 2014 to 2016, 865 men underwent prostate MRI and MRI/ultrasound (US) fusion biopsy (FB). A subset of 90 FB-naïve men with 96 PI-RADSv2 category 3 TZ lesions was identified. Patients were imaged at 3 T using a body coil. Images were assigned a PI-RADSv2 category by an experienced radiologist. Using clinical data and imaging features, we performed univariate and multivariate analyses to identify predictors of clinically significant PCA.

RESULTS: The mean patient age was 66 years, and the mean prostate-specific antigen density (PSAD) was 0.13 ng/mL2. PCA was detected in 34 of 96 (35%) lesions, 14 of which (15%) harbored clinically significant PCA. In univariate analysis, DWI score, prostate volume, and PSAD were significant predictors (p < 0.05) of clinically significant PCA with a suggested significance for apparent diffusion coefficient (ADC) and prostate-specific antigen value (p < 0.10). On multivariate analysis, PSAD and lesion ADC were the most important covariates. The combination of both PSAD of 0.15 ng/mL2 or greater and an ADC value of less than 1000 mm2/s yielded an AUC of 0.91 for clinically significant PCA (p < 0.001). If FB had been restricted to these criteria, only 10 of 90 men would have undergone biopsy, resulting in diagnosis of clinically significant PCA in 60% with eight men (9%) misdiagnosed (false-negative).

CONCLUSION: The yield of FB in men with PI-RADSv2 category 3 TZ lesions for clinically significant PCA is 15% but significantly improves to 60% (AUC > 0.9) among men with PSAD of 0.15 ng/mL2 or greater and lesion ADC value of less than 1000 mm2/s.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Felker ER, Raman SS, Margolis DJ, et al. Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary? AJR Am J Roentgenol. 2017. PMID: 28858541. doi:10.2214/AJR.17.18008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。